Literature DB >> 11877350

Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension.

Michael Bauer1, Heinrike Wilkens, Frank Langer, Sven O Schneider, Henning Lausberg, Hans-Joachim Schäfers.   

Abstract

BACKGROUND: The pulmonary circulation is an important site for the production and clearance of endothelin (ET)-1, a potent vasoactive and mitogenic peptide. Increased plasma ET-1 levels are observed in pulmonary arterial hypertension (PHT) and may contribute to the regulation of pulmonary vascular resistance, as well as to proliferative changes in the pulmonary vascular bed. METHODS AND
RESULTS: We prospectively assessed changes in plasma big ET-1 levels and changes in ET(A) and ET(B) receptor gene expression in 14 consecutive patients undergoing pulmonary thromboendarterectomy for thromboembolic PHT. Plasma big ET-1 levels were higher in patients with PHT (median, 2.2 pg/mL; 25th to 75th percentile, 1.5 to 3.0 pg/mL) compared with age-matched controls (median, 1.2 pg/mL; 25th to 75th percentile, 1.0 to 1.4 pg/mL; P=0.002). In addition to increased plasma big ET-1 levels, selective upregulation of ET(B) receptor mRNA transcripts and immunoreactive protein in the pulmonary artery was observed in the patients; however, ET(A) receptor gene expression was unaffected.
CONCLUSIONS: These data suggest that changes in the ET signaling system in PHT caused by thromboembolic disease are not limited to an increased production of ET-1: they also affect ET receptor gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877350     DOI: 10.1161/hc0902.105719

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  33 in total

Review 1.  [Endothelin system and inhalation of iloprost in pulmonary hypertension].

Authors:  M Bauer; H Wilkens
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

Review 2.  [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment].

Authors:  K Ahmadi-Simab; W L Gross
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 3.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

Review 4.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

Review 5.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

6.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Sanjiv Kumar; Shruti Sharma; Saurabh Aggarwal; Frank Schneider; Danny Jonigk; Stephen M Black; Stevan P Tofovic
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

Review 7.  [Thromboembolism and pulmonary hypertension].

Authors:  D Drömann
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

8.  Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha.

Authors:  Nitin Patel; Caryn S Gonsalves; Punam Malik; Vijay K Kalra
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

9.  Diagnosis and vasculopathy in chronic thromboembolic pulmonary hypertension.

Authors:  Nobuhiro Tanabe
Journal:  Ann Vasc Dis       Date:  2010-03-29

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.